ArticleBioresources and bioprocessing2026
Optimization of cultivation strategies for production of recombinant human papillomavirus type 58 major capsid protein L1 in Hansenula polymorpha.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomaviruses (HPVs) are a major cause of cervical cancer, which ranks fourth among cancers in women worldwide. A prophylactic vaccine composed of virus-like particles (VLPs) formed by the major capsid protein L1 of human papillomavirus (HPV) effectively prevents HPV infection but provides limited cross-protection against other HPV subtypes, highlighting the importance of multivalent prophylactic vaccines. In this study, cultivation conditions for recombinant HPV58 L1 protein production in the yeast Hansenula polymorpha were optimized to enhance growth and the volumetric yield of L1 protein. The results indicated that induction with methanol (at 1% v/v) was necessary for HPV58 L1 production in SYN6 medium, whereas a cultivation temperature of 37 °C was optimal for growth and production of HPV58 L1 protein. Subsequently, SYN6 medium supplemented with 10 g/L of either Hy-Express™ System II or HySoy was evaluated in batch and fed-batch bioreactor cultivations. Fed-batch cultivation with HySoy supplementation under a constant feeding rate achieved an OD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.